Fennec Pharmaceuticals (FENC) Misses Q2 EPS by 18c

Fennec Pharmaceuticals (NASDAQ: FENC) reported Q2 EPS of ($0.20), $0.18 worse than the analyst estimate of ($0.02). Revenue for the quarter came in at $7.3 million versus the consensus estimate of $11.05 million.

For earnings history and earnings-related data on Fennec Pharmaceuticals (FENC) click here.

You May Also Be Interested In

• Trump: nominate Heidi Overton, MD, PhD, as our next FDA commissioner
• Legence Corp (LGN) PT Raised to $130 at Tigress Financial Partners
• Stripe agrees to acquire AI model routing platform OpenRouter